Literature DB >> 17867371

Nonalcoholic fatty liver disease: pathogenesis, identification, progression, and management.

Eric Yan1, Francisco Durazo, Myron Tong, Kurt Hong.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of liver diseases in the absence of significant alcohol consumption, and its incidence is paralleling the increasing numbers of overweight and obese individuals worldwide. This review discusses the pathogenesis of NAFLD, including the roles potentially played by specific adipokines, such as TNF-alpha, leptin, and adiponectin. Clinical features, diagnosis, and potential methods of management are also addressed to assist practitioners with the management of this growing population of patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17867371     DOI: 10.1301/nr.2007.aug.376-384

Source DB:  PubMed          Journal:  Nutr Rev        ISSN: 0029-6643            Impact factor:   7.110


  18 in total

Review 1.  Signal transductions and nonalcoholic fatty liver: a mini-review.

Authors:  Lu Zeng; Wai J Tang; Jin J Yin; Bei J Zhou
Journal:  Int J Clin Exp Med       Date:  2014-07-15

2.  Non-invasive diagnosis of non-alcoholic fatty liver disease (NAFLD) using ultrasound image echogenicity.

Authors:  Alex Benjamin; Rebecca Zubajlo; Kai Thomenius; Manish Dhyani; Kanakaraju Kaliannan; Anthony E Samir; Brian W Anthony
Journal:  Conf Proc IEEE Eng Med Biol Soc       Date:  2017-07

3.  Protective effect of boswellic acids versus pioglitazone in a rat model of diet-induced non-alcoholic fatty liver disease: influence on insulin resistance and energy expenditure.

Authors:  Sawsan A Zaitone; Bassant M Barakat; Shymaa E Bilasy; Manal S Fawzy; Eman Z Abdelaziz; Noha E Farag
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-02-24       Impact factor: 3.000

Review 4.  Clinical approaches to non-alcoholic fatty liver disease.

Authors:  Katherine J P Schwenger; Johane P Allard
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

5.  Noninvasive quantitation of human liver steatosis using magnetic resonance and bioassay methods.

Authors:  Gaspard d'Assignies; Martin Ruel; Abdesslem Khiat; Luigi Lepanto; Miguel Chagnon; Claude Kauffmann; An Tang; Louis Gaboury; Yvan Boulanger
Journal:  Eur Radiol       Date:  2009-03-11       Impact factor: 5.315

6.  Downregulation of adiponectin/AdipoR2 is associated with steatohepatitis in obese mice.

Authors:  Yanhua Peng; Drew Rideout; Steven Rakita; Mini Sajan; Robert Farese; Min You; Michel M Murr
Journal:  J Gastrointest Surg       Date:  2009-09-18       Impact factor: 3.452

Review 7.  Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.

Authors:  Erin K Spengler; Rohit Loomba
Journal:  Mayo Clin Proc       Date:  2015-07-26       Impact factor: 7.616

8.  UCP1 -3826 AG+GG genotypes, adiponectin, and leptin/adiponectin ratio in severe obesity.

Authors:  G Labruna; F Pasanisi; C Nardelli; G Tarantino; D F Vitale; R Bracale; C Finelli; M P Genua; F Contaldo; L Sacchetti
Journal:  J Endocrinol Invest       Date:  2009-03-26       Impact factor: 4.256

9.  Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial.

Authors:  Carly Eckard; Renee Cole; Joshua Lockwood; Dawn M Torres; Christopher D Williams; Janet C Shaw; Stephen A Harrison
Journal:  Therap Adv Gastroenterol       Date:  2013-07       Impact factor: 4.409

10.  Exploration of a symptoms experience in people with obesity-related nonalcoholic fatty liver disease.

Authors:  Lori D Houghton-Rahrig; Debra L Schutte; Alexander von Eye; Jenifer I Fenton; Barbara A Given; Norman G Hord
Journal:  Nurs Outlook       Date:  2013 Jul-Aug       Impact factor: 3.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.